← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs
valbenazine
N07XX13
Forms & Strengths
- Capsule: 40 mg
- Capsule: 60 mg
- Capsule: 80 mg
Adult Dosing
- Tardive dyskinesia: Initial 40 mg once daily, increase to 80 mg once daily after 2 weeks
- Tardive dyskinesia (alternative): May use 60 mg once daily based on response and tolerability
- Hepatic impairment (moderate to severe): 40 mg once daily
- CYP2D6 poor metabolizers or concomitant strong CYP3A4 inhibitors: 40 mg once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of tardive dyskinesia in adults
- Treatment of chorea associated with Huntington's disease in adults
Mechanism of Action
- Reversible vesicular monoamine transporter 2 (VMAT2) inhibitor
- Decreases uptake of monoamines into synaptic vesicles, depleting striatal dopamine stores
Contraindications
- Known hypersensitivity to valbenazine or its excipients
- Concomitant use with strong MAO inhibitors
Adverse Reactions
- Somnolence and sedation
- Anticholinergic effects (dry mouth, constipation)
- Balance disorders, falls, dizziness
- Parkinsonism and extrapyramidal symptoms
- QT interval prolongation
Drug Interactions
- Strong CYP3A4 inhibitors (increase valbenazine exposure, dose reduction recommended)
- Strong CYP3A4 inducers (decrease valbenazine efficacy, concomitant use not recommended)
- Strong CYP2D6 inhibitors (increase valbenazine exposure)
- Drugs that prolong the QT interval (additive risk of arrhythmia)
Curated Content: Needs Vetting Before Put to Clinical Use